Form 4 for VOR Vor Biopharma Inc.
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-05 · accession 0001511034-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-09 | 2025-12-05 | VOR | Mahatme Sandesh | CFO | D - Sale to Iss | $0.00 | -694.1K | 0 | -100% | $0 |
| D | 2025-12-09 | 2025-12-05 | VOR | Mahatme Sandesh | CFO | A - Grant | $0.00 | +1.39M | 1.39M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-05 | D | D | 694,137 | $0.00 | 0 | D | — | — | (F2) On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025. (F1) On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-12-05 | A | A | 1,388,274 | $0.00 | 1,388,274 | D | $17.80 · — to 2035-12-04 | 1,388,274 Common Stock | (F3) The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above. (F4) 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |